Abstract
Adipose tissue (AT) is now widely accepted as a key secretary organ, as well as an energy storage depot. It secretes a series of cytokines, hormones and bioactive molecules: adipokines. Adiponectin is an abundant systemic adipokine that uniquely is reduced in obesity and increases on weight loss, is anti-inflammatory, promotes insulin sensitivity and affords cardiometabolic protection. It was considered a true adipokine, in that it is exclusively generated by the adipocytes of the adipose tissue. However, recent evidence points to it being secreted by a range of other organs. This review summarizes the non-adipose sources of adiponectin especially that derived from the endothelium, its vasoprotective role and intracellular signalling pathways. Endothelium derived adiponectin may potentially be a new target for clinical intervention in cardiovascular disease.
Keywords: Adiponectin, coronary artery bypass grafting, endothelium, perivascular adipose tissue.
Current Vascular Pharmacology
Title:Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Volume: 14 Issue: 2
Author(s): Lei Shen, Ian M. Evans, Domingos Souza, Mats Dreifaldt, Michael R. Dashwood and Mohamed-Ali Vidya
Affiliation:
Keywords: Adiponectin, coronary artery bypass grafting, endothelium, perivascular adipose tissue.
Abstract: Adipose tissue (AT) is now widely accepted as a key secretary organ, as well as an energy storage depot. It secretes a series of cytokines, hormones and bioactive molecules: adipokines. Adiponectin is an abundant systemic adipokine that uniquely is reduced in obesity and increases on weight loss, is anti-inflammatory, promotes insulin sensitivity and affords cardiometabolic protection. It was considered a true adipokine, in that it is exclusively generated by the adipocytes of the adipose tissue. However, recent evidence points to it being secreted by a range of other organs. This review summarizes the non-adipose sources of adiponectin especially that derived from the endothelium, its vasoprotective role and intracellular signalling pathways. Endothelium derived adiponectin may potentially be a new target for clinical intervention in cardiovascular disease.
Export Options
About this article
Cite this article as:
Shen Lei, Evans M. Ian, Souza Domingos, Dreifaldt Mats, Dashwood R. Michael and Vidya Mohamed-Ali, Adiponectin: An Endothelium-Derived Vasoprotective Factor?, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202210128
DOI https://dx.doi.org/10.2174/1570161114666151202210128 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets Functional Recovery After Stroke: A Review of Current Developments in Stroke Rehabilitation Research
Reviews on Recent Clinical Trials Distribution of Left Ventricular Thrombus among Patients with Significantly Impaired Systolic Function
New Emirates Medical Journal A Review of Gene Expression Profiling of Human Embryonic Stem Cell Lines and their Differentiated Progeny
Current Stem Cell Research & Therapy Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors
Current Enzyme Inhibition Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design The Accuracy of Self-Reported Hypertension: A Systematic Review and Meta-Analysis
Current Hypertension Reviews MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Employment of Quality by Design Approach via Response Surface Methodology to Optimize and Develop Modified-release Formulation of Hydrochlorothiazide
Current Computer-Aided Drug Design The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design